CNC vs. HUM, MOH, CI, ELV, IDXX, ALC, IQV, TAK, HLN, and GEHC
Should you be buying Centene stock or one of its competitors? The main competitors of Centene include Humana (HUM), Molina Healthcare (MOH), The Cigna Group (CI), Elevance Health (ELV), IDEXX Laboratories (IDXX), Alcon (ALC), IQVIA (IQV), Takeda Pharmaceutical (TAK), Haleon (HLN), and GE HealthCare Technologies (GEHC). These companies are all part of the "medical" sector.
Centene (NYSE:CNC) and Humana (NYSE:HUM) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.
Centene has higher revenue and earnings than Humana. Centene is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.
Centene currently has a consensus target price of $85.23, suggesting a potential upside of 10.53%. Humana has a consensus target price of $424.50, suggesting a potential upside of 25.01%. Given Humana's higher probable upside, analysts clearly believe Humana is more favorable than Centene.
Centene received 129 more outperform votes than Humana when rated by MarketBeat users. Likewise, 73.25% of users gave Centene an outperform vote while only 64.15% of users gave Humana an outperform vote.
Centene has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Humana has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500.
In the previous week, Humana had 10 more articles in the media than Centene. MarketBeat recorded 19 mentions for Humana and 9 mentions for Centene. Centene's average media sentiment score of 0.69 beat Humana's score of 0.36 indicating that Centene is being referred to more favorably in the media.
Humana has a net margin of 1.82% compared to Centene's net margin of 1.76%. Humana's return on equity of 17.76% beat Centene's return on equity.
93.6% of Centene shares are owned by institutional investors. Comparatively, 92.4% of Humana shares are owned by institutional investors. 0.3% of Centene shares are owned by insiders. Comparatively, 0.3% of Humana shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Humana beats Centene on 10 of the 17 factors compared between the two stocks.
Get Centene News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
